|
|
 |
|
Viewing report
|
|
|
|
Gilead to Acquire Pharmasset for $11 Billion
GlobalData, Nov 2011, Pages: 4
Gilead to Acquire Pharmasset for $11 Billion - Deal Analysis from GlobalData
Summary
GlobalData, the industry analysis specialist, has released its new report, “Gilead to Acquire Pharmasset for $11 Billion”. The report is an essential source of information and analysis on Gilead’s decision to acquire Pharmasset. The report provides insights on the rationale of the deal and its strategic implications. Most importantly, the report provides valuable insights on the strategies of Gilead, which lead to the acquisition and company’s competitive position in the market after the acquisition. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key developments in the hepatitis C virus (HCV) infection market prior to the acquisition and future implications of Gilead’s decision to acquire Pharmasset on the market. Its scope includes -
- HCV infection market dynamics
- Assessment of current unmet need in the HCV infection market
- Rationale behind the acquisition
- Pipeline assessment of Gilead and Pharmasset in HCV therapeutics
- Strategic Implications of the acquisition
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies by understanding Gilead’s business strategy and its competitive position in HCV infection market
- Formulate effective business decisions ahead in HCV infection market
- Organize your sales and marketing efforts by identifying the various strategies being followed by the pharmaceutical companies
|
|
|
|
